LENZ Therapeutics Inc (LENZ) USD0.001

Sell:$26.87Buy:$26.94$1.67 (5.84%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$26.87
Buy:$26.94
Change:$1.67 (5.84%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$26.87
Buy:$26.94
Change:$1.67 (5.84%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

Key people

Eef Schimmelpennink
President, Chief Executive Officer, Director
Perry Karsen
Independent Chairman of the Board
Matthew Porteus
Director
Abraham Bassan
Independent Director
Jerel Davis
Independent Director
Kristen M. Hege
Independent Director
Click to see more

Key facts

  • EPIC
    LENZ
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US52635N1037
  • Market cap
    $742.29m
  • Employees
    42
  • Shares in issue
    27.56m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.